October 14, 2016
Potentially anticompetitive practices in the pharmaceutical industry are among topics to be discussed at a global meeting on competition next week in Geneva, Switzerland. Referring to agreements which occur when a patent holder compensates a competitor to delay or abandon the launch of a generic drug, United Nations Conference on Trade and Development (UNCTAD) economist Ebru Gokce commented: "We're not questioning the merit of patent protection. We're questioning the anti-competitive nature of practices, such as pay-for-delay agreements, that prolong market exclusivity." The 15th Intergovernmental Group of Experts Meeting on Competition Law and Policy takes place from October 19 to 21.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.